Novo wins EU recommendation for two-in-one diabetes drug
July 25, 2014 at 07:18 AM EDT
LONDON, July 25 (Reuters) - A Novo Nordisk drug combining its long-acting insulin degludec with its type 2 diabetes treatment Victoza has been recommended for approval in Europe, in an important boost for the Danish company.